0.49
0.49 (0%)
As of Feb 14, 2025
Sesen Bio, Inc. [CARM]
Source:
Company Overview
Carisma Therapeutics Inc. is a biotechnology company focused on applying our industry leading expertise in macrophage engineering to develop transformative therapies to treat serious diseases including liver fibrosis and cancer.
| Country | United States |
| Headquarters | philadelphia, pennsylvania |
| Phone Number | 2674916422 |
| Industry | manufacturing |
| CEO | Steven Kelly |
| Website | www.sesenbio.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $19.6 |
| Operating Profit | $-62.2 |
| Net Income | $-60.5 |
| Net Cash | $-59.7 |
Profit Ratios
| Gross Margin | $19.6 |
| Operating Margin | -316.7 |
| Profit as % of Revenues | -32.5% |
| Profit as % of Assets | -100.8% |
| Profit as % of Stockholder Equity | 216.7% |
Management Effectiveness
| Return on Equity | 216.7% |
| Return on Assets | -198.6% |
| Turnover Ratio | 32.7% |
| EBITA | $-62.2 |
Balance Sheet and Cash Flow Measures
| Total Assets | $30.5 |
| Total Liabilities | $58.4 |
| Operating Cash Flow | $-59.9 |
| Investing Cash Flow | $-0.1 |
| Financing Cash Flow | $0.3 |
